A5056151772- Liver Disease Diagnosis and Treatment
- Diet, Metabolism, and Disease
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Alcohol Consumption and Health Effects
- Diet and metabolism studies
- Hepatitis C virus research
- Pancreatitis Pathology and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cardiovascular Disease and Adiposity
- Liver Diseases and Immunity
- Skin and Cellular Biology Research
- Metabolism, Diabetes, and Cancer
- Gout, Hyperuricemia, Uric Acid
- Nutrition and Health in Aging
- Adipose Tissue and Metabolism
- Adipokines, Inflammation, and Metabolic Diseases
- Diabetes Treatment and Management
- Folate and B Vitamins Research
- Diabetes and associated disorders
- RNA regulation and disease
- Regulation of Appetite and Obesity
- Porphyrin Metabolism and Disorders
- Prion Diseases and Protein Misfolding
- Galectins and Cancer Biology
The First Affiliated Hospital, Sun Yat-sen University
2016-2025
Sun Yat-sen University
2016-2025
Office for National Statistics
2024
University Gastroenterology
2022
BackgroundTraditional classification systems of metabolic-associated fatty liver disease (MAFLD) do not account for the high rate extrahepatic complications. To create a new MAFLD using metabolic parameters to identify risks complications more accurately.MethodsThe retrospective study included patients from First Affiliated Hospital Sun Yat-sen University model development, and was validated respectively Chinese cohort UK Biobank database. Cluster analysis with k-means cluster built age,...
Abstract Background and Aim The introduction of the latest nomenclature, metabolic associated steatotic liver disease (MASLD), proposed by multi‐society without Asian society consensus statement, aims to redefine diagnostic criteria for fatty (MAFLD). However, its effect on epidemiology in Asia remains unclear. Method We conducted a population‐based cross‐sectional survey using multistage stratified random sampling participants from Guangzhou, representative area China (ChiCTR2000033376)....
The liver effect of orlistat as a weight control treatment in patients with nonalcoholic fatty disease (NAFLD) obesity remains undetermined. This study quantified fat improvement by Chinese cohort NAFLD accompanied obesity, diagnosed lower body mass index threshold than that for White patients.We conducted parallel-group, open-label, 24-week, randomized clinical trial registered at the Clinical Trial Registry (ChiCTR-IPR-17012258). Obese participants were 1:1.5 to intervention group or...
As the nonalcoholic fatty liver disease (NAFLD) epidemic matures, understanding how metabolic changes in NAFLD development vary over age distribution is important to guide precise prevention. We aimed clarify trends age-specific incidence.We conducted a 4-year longitudinal retrospective cohort study enrolling 10,240 consecutive healthy individuals who received annual physical examination during 2012-2019. Baseline and dynamic metabolism hepatic steatosis determined with ultrasound were...
Losing weight by lifestyle interventions is the first-line treatment for metabolic-associated fatty liver disease (MAFLD) but limited low compliance.This study aimed to compare effects of orlistat or an experimental high-protein/lower-carbohydrate diet with a control in Asian patients obesity and MAFLD.A total 118 MAFLD confirmed MRI-based proton density fat fraction Dixon sequence were enrolled allocated group, group 24 wk. The primary endpoint was relative change content (LFC) assessed...
Current evidence on the impact of ethnic disparities metabolic-associated steatotic liver disease (MASLD) is limited to individual studies with small sample sizes from specific regions. This network meta-analysis aimed assess variations in metabolism and histological characteristics MASLD among four ethnicities. Observational involving at least two groups (White, Black, Asian, Hispanic) were identified PubMed, Embase, Web Science databases up May 7th, 2024, for inclusion this study. The...
Background: Previous studies have verified that metabolic dysfunction-associated steatotic liver disease (MASLD) confered higher risk of coronary atherosclerosis development. However, whether MASLD influence prognosis after drug-eluting stent (DES) implantation treatment remain not known. Methods: In this retrospective observational study, 301 included cardiovascular (CVD) patients who underwent re-coronary angiography the first successful DES-based percutaneous intervention. All received...
Whether the weight-loss plateau and its values differ in obesity with or without metabolic dysfunction-associated steatotic liver disease (MASLD) undergoing continuous lifestyle intervention remains unknown. We aimed to investigate this problem. This prospective observational cohort study included 305 patients MASLD 103 matched individuals non-MASLD from January 2015 April 2023, a 12-month follow-up monitor weight changes. Liver biochemistry, fat content MRI-PDFF, stiffness measurement via...
Tissue spatial interaction in the liver, including interplay among immune cells, blood vessels, sinusoidal endothelial bile ducts, stellate hepatic progenitor and hepatocytes, is crucial not only for normal organogenesis but also disease development. Metabolic dysfunction-associated steatotic liver (MASLD) has emerged as most prevalent disease, with heterogeneous mechanisms involving cross-talk between hepatocytes stromal cells under metabolic stress, inflammation, fibrosis. Developing 3D...
The recent FDA-approval of resmetirom for treating metabolic dysfunction-associated steatohepatitis (MASH) in patients necessitates patient selection significant fibrosis or higher (≥F2). No existing vibration-controlled transient elastography (VCTE) algorithm targets ≥F2. ALADDIN study addressed this gap by introducing a machine-learning-based web calculator that estimates the likelihood using routine laboratory parameters with and without VCTE. Our included Training set 827 patients,...
Background: The clinical burden and natural history of non-alcoholic fatty liver disease (NAFLD) vary globally. We aimed to investigate NAFLD-related mortality profiles in hospitalized patients southern China. Methods: A multicenter retrospective investigation with a 10-year study period (2009–2018) analyzed 10,071 deaths during hospitalization (NAFLD: 2,015; other diseases: 1,140; without 6,916) was performed using multiple cause death analysis. Medical histories biochemistry imaging...
The consistency in steatosis grading between magnetic resonance imaging-based proton density fat fraction (MRI-PDFF) and controlled attenuation parameter (CAP) before after treatment remains unclear. This study aimed to compare the diagnostic accuracy of MRI-PDFF CAP using liver biopsy as standard evaluate value monitoring changes with during follow-up utilizing a reference.Consecutive patients from cohort randomized trial were included this classified into 3 groups (the biopsy, orlistat...
Serum uric acid (SUA) is regarded as an independent risk factor for nonalcoholic fatty liver disease (NAFLD). However, the role of SUA in new diagnosis flowchart metabolic-associated (MAFLD) remains unclear. A cross-sectional study enrolled consecutive individuals with ultrasonography and magnetic resonance imaging−based proton density fat fraction (MRI-PDFF) measurements First Affiliated Hospital Sun Yat-sen University from January 2015 to December 2021. All patients were divided into four...
The study aimed to explore the relationships of skeletal muscle mass with disease severity in metabolic-associated fatty liver (MAFLD) patients different methods. Consecutive subjects undergoing bioelectrical impedance analysis were included. steatosis grade and fibrosis evaluated by MRI-derived proton density fat fraction two-dimensional shear wave elastography. appendicular (ASM) was adjusted height2 (ASM/H2), weight (ASM/W) BMI (ASM/BMI). Overall, 2223 (50·5 %, MAFLD; 46·9 male) included,...
Nonobese metabolic dysfunction-associated fatty liver disease (MAFLD) is paradoxically associated with improved and pathological features at diagnosis but similar cardiovascular diseases (CVD) prognosis to obese MAFLD. We aimed utilize the metabolomics identify potential metabolite profiles accounting for this phenomenon.This prospective multicenter cross-sectional study was conducted in China enrolling derivation validation cohorts. Liquid chromatography coupled mass spectrometry gas...